Lowe v. Tandem Diabetes Care, Inc.

CourtDistrict Court, S.D. California
DecidedDecember 5, 2023
Docket3:23-cv-01657
StatusUnknown

This text of Lowe v. Tandem Diabetes Care, Inc. (Lowe v. Tandem Diabetes Care, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lowe v. Tandem Diabetes Care, Inc., (S.D. Cal. 2023).

Opinion

1 2 3 4 5 6 7 8 9 UNITED STATES DISTRICT COURT 10 SOUTHERN DISTRICT OF CALIFORNIA 11 12 CAREY LOWE, individually and on Case No.: 3:23-cv-01657-H-BLM behalf of all others similarly situated, 13 ORDER: Plaintiff, 14 v. (1) DENYING MASON RAINES 15 MOTION FOR APPOINTMENT TANDEM DIABETES CARE INC., 16 AS LEAD PLAINTIFF AND JOHN F. SHERIDAN, BRIAN B. APPROVAL OF HIS SELECTION 17 HANSEN, AND LEIGH A. OF COUNSEL; VOSSELLER, 18 Defendants. (2) DENYING THE MARTEL 19 FAMILY’S MOTION FOR 20 APPOINTMENT AS LEAD PLAINTIFFS AND APPROVAL 21 OF THEIR SELECTION OF 22 COUNSEL; AND

23 (3) GRANTING THE MOVANTS’ 24 JOINT MOTION TO APPOINT CO-LEAD PLAINTIFFS AND CO- 25 LEAD COUNSEL 26 [Doc. Nos. 3, 4, 5.] 27 28 On November 7, 2023, Mason Raines (“Raines”) filed a motion for appointment as 1 lead plaintiff and for approval of his selection of lead counsel. (Doc. No. 3.) That same 2 day, Thomas O. Martel and Linna Rae Martel (collectively, the “Martel Family”) filed a 3 motion for appointment as lead plaintiffs and for approval of their selection of lead counsel. 4 (Doc. No. 4.) 5 On November 22, 2022, Raines and the Martel Family (together, “Movants”) filed 6 a joint motion for appointment as co-lead plaintiffs and for their respective selections of 7 counsel to serve as co-lead counsel. (Doc. No. 5.) Movants represent that their respective 8 counsel met-and-conferred with counsel for Defendants Tandem Diabetes Care Inc., John 9 F. Sheridan, Brian B. Hansen, and Leigh A. Vosseller (collectively, “Defendants”). (Id. at 10 3.) Movants state that Defendants take no position regarding Movants’ pending motions 11 for lead plaintiff, the joint motion for appointment as co-lead plaintiffs, and Movants’ 12 respective selections of co-lead counsel. (Id.) No other competing motions for lead 13 plaintiff have been filed. 14 A hearing on this matter was scheduled for December 11, 2023 at 10:30 a.m. The 15 Court, pursuant to its discretion under Local Rule 7.1(d)(1), determined the matter was 16 appropriate for resolution without oral argument, submitted the motions on the parties’ 17 papers, and vacated the hearing. (Doc. No. 6.) For the reasons set forth below, the Court 18 grants Movants’ joint motion for appointment as co-lead plaintiffs and approves their 19 selections for co-lead counsel. The Court denies Movants’ individual motions as moot. 20 (Doc. Nos. 3, 4.) 21 BACKGROUND 22 On September 8, 2023, Plaintiff Carey Lowe (“Plaintiff Lowe”), through his counsel 23 Levi & Korsinsky LLP (“Levi & Korsinsky”), filed a securities class action complaint 24 against Defendants Tandem Diabetes Care, Inc. (“Tandem” or the “Company”), John F. 25 Sheridan, Brian B. Hansen, and Leigh A. Vosseller. (Doc. No. 1, Compl.) The complaint 26 alleges that between August 3, 2022, and November 2, 2022, inclusive (the “Class 27 Period”), Defendants defrauded investors in violation of Sections 10(b) and 20(a) of the 28 Securities Exchange Act, 15 U.S.C. §§ 78j(b), 78t(a), and U.S. Securities and Exchange 1 Commission Rule 10b-5, 17 C.F.R. § 240.10b-5. Specifically, the complaint asserts that 2 during the Class Period, Defendants made materially false and/or misleading statements 3 regarding Tandem’s projected revenue and sales for the year ending in 2022. (Compl. ¶ 4 2.) Plaintiff Lowe claims Tandem investors incurred significant losses when Tandem 5 revised its 2022 forecast downward from a range of $835 million to $845 million to a range 6 of $800 to $805 million. Plaintiff Lowe represents that the Company’s announcement 7 caused Tandem’s common stock to decline drastically, dropping 30.4% from November 2, 8 2022 to November 3, 2022. (Id. ¶¶ 4–5.) 9 In response to a notice that was published after Plaintiff Lowe filed his class action 10 complaint, Raines and the Martel Family filed their motions to be appointed as lead 11 plaintiff and for approval of their selection of lead counsel. (Doc. Nos. 3, 4.) Raines alleges 12 he purchased 1,000 shares of Tandem stock during the Class Period and suffered financial 13 losses of approximately $12,232.67. (Doc. No. 3-4, Ex. B to Declaration of Adam M. 14 Apton (“Apton Decl.”).) The Martel Family alleges they purchased 455 shares of Tandem 15 during the Class Period and suffered financial losses of approximately $7,792. (Doc. No. 16 4-3, Ex. A to Declaration of Jennifer Pafiti (“Pafiti Decl.”).) On November 22, 2023, after 17 reviewing each other’s motions, Movants filed a joint motion to appoint themselves as co- 18 lead plaintiffs and to approve their respective selections of counsel as co-lead counsel. 19 (Doc. No. 5.) Movants represent that it will be in the best interests of the class for Movants 20 to serve as co-lead plaintiffs and for their respective selections of counsel to serve as co- 21 lead counsel in this action. (Id. at 3.) 22 DISCUSSION 23 I. Appointment of Co-Lead Plaintiffs 24 Under the Private Securities Litigation Reform Act (“PSLRA”), the district court 25 shall appoint as lead plaintiff “the member or members of the purported plaintiff class that 26 the court determines to be most capable of adequately representing the interests of class 27 members.” 15 U.S.C. § 78u-4(a)(3)(B)(i). The presumptively most adequate plaintiff is 28 the one who: (1) has either filed the complaint or brought a motion for appointment as lead 1 plaintiff in response to the publication of notice; (2) “has the largest financial interest in 2 the relief sought by the class;” and (3) “otherwise satisfies the requirements of Rule 23 of 3 the Federal Rules of Civil Procedure.” Id. § 78u-4(a)(3)(B)(iii)(I)(aa)–(cc). “In other 4 words, the district court must compare the financial stakes of the various plaintiffs and 5 determine which one has the most to gain from the lawsuit. It must then focus its attention 6 on that plaintiff and determine, based on the information he has provided in his pleadings 7 and declarations, whether he satisfies the requirements of Rule 23(a), in particular those of 8 ‘typicality’ and ‘adequacy.’” In re Cavanaugh, 306 F.3d 726, 730 (9th Cir. 2002) 9 (emphasis in original). Once established, this presumption may be rebutted only upon 10 proof that the presumptive lead plaintiff: (1) “will not fairly and adequately protect the 11 interests of the class; or” (2) “is subject to unique defenses that render such plaintiff 12 incapable of adequately representing the class.” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II)(aa)– 13 (bb). 14 The decision to appoint “co-lead plaintiffs is within the discretion of the [district] 15 [c]ourt.” Miller v. Ventro Corp., No. 01-CV-1287, 2001 WL 34497752, at *9 (N.D. Cal. 16 Nov. 28, 2001). Here, Movants assert that it is in the best interests of the class for Raines 17 and the Martel Family to join efforts and serve as co-lead plaintiffs. (Doc. No. 5 at 3.) The 18 Court agrees and exercises its discretion to appoint co-lead plaintiffs in this action so long 19 as (1) Movants are the presumptively most adequate plaintiff under the PSLRA’s three- 20 pronged test; and (2) the presumption is not rebutted. 21 A. Preliminary Procedural Requirements. 22 Pursuant to the PSLRA, no later than 20 days after filing a class action securities 23 complaint, a private plaintiff or plaintiffs must publish a notice advising members of the 24 purported plaintiff class of the pendency of the action, the claims asserted, and that any 25 member of the purported class may move the court to serve as lead plaintiff. 15 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Lowe v. Tandem Diabetes Care, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lowe-v-tandem-diabetes-care-inc-casd-2023.